surfactant

(redirected from Pulmonary surfactant)
Also found in: Dictionary, Thesaurus, Medical, Wikipedia.

surfactant

[sər′fek·tənt]
(materials)

surfactant

A chemical wetting agent; added to water to improve its penetration into a material; often useful in reducing the amount of water required in removing a material from the surface on which it has been applied.
References in periodicals archive ?
On that point Brubaker was most impressed with Anthony Colucci's pulmonary surfactant studies, which, he wrote, came close to understanding the cause, or mechanism, of how smoking triggers emphysema.
Respiratory distress syndrome (RDS) in premature infants is caused by developmental insufficiency of pulmonary surfactant production and structural immaturity of the lungs.
Brief report: Deficiency of pulmonary surfactant protein B in congenital alveolar proteinosis.
Pulmonary surfactant concentration will be higher in the fluid surrounding the fetal mouth.
Discovery Labs' technology produces a peptide-containing synthetic surfactant (KL-4 surfactant) that is structurally similar to pulmonary surfactant.
Ozone reacts with unsaturated C=C bonds, amino acids, and other chemical structures, and ozone exposure can lead to edema, inflammation, and epithelial cell damage, contributing to lung injury and pulmonary surfactant derangement (2).
KL-4 is a 21-amino acid peptide with structural similarities to pulmonary surfactant protein B (SP-B), the surfactant protein most important for normal respiratory function.
Presently, Discovery is developing its synthetic pulmonary surfactant Surfaxin(R), invented at The Scripps Research Institute and initially developed by Johnson and Johnson, to treat predominately direct causes of ARDS/ALI in adults, MAS in full-term newborns, and respiratory distress syndrome (RDS) in premature infants.
Discovery Labs' technology platform includes a novel synthetic peptide-containing (KL4) surfactant that is structurally similar to naturally occurring pulmonary surfactant and proprietary drug delivery technologies being developed to enable efficient delivery of aerosolized KL4 surfactant.
Discovery) (Nasdaq small cap: DSCO, DSCOU) announced that it has begun preclinical research into converting its unique pulmonary surfactant, Surfaxin(R), into aerosolized forms for the potential therapy of asthma, chronic obstructive pulmonary disease (COPD), acute and chronic bronchitis and a variety of other respiratory diseases.